NuvOx Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oxygen therapeutic solutions for diseases where hypoxia plays a critical role. Its primary product candidate, NanO2, is an intravenously administered emulsion of dodecafluoropentane that converts to gas in the body, enhancing oxygen delivery. The company is conducting clinical research primarily in the areas of acute ischemic stroke, glioblastoma multiforme (GBM), acute respiratory distress syndrome (ARDS), and sickle cell anemia, addressing significant unmet medical needs.
Not disclosed in the provided filing text.
The net proceeds from this offering are intended to be used to complete ongoing clinical trials, conduct a planned Phase II trial for ARDS, and prepare for a pivotal Phase III trial for GBM.
This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.
The proposed ticker is NUOX. Underwriters on the deal include ThinkEquity LLC. NuvOx Therapeutics, Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.
NuvOx Therapeutics, Inc. has filed 3 times, starting with a S1/A on Sep 16, 2026.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with NuvOx Therapeutics, Inc..
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/nuvox-therapeutics" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="NuvOx Therapeutics, Inc. — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/nuvox-therapeutics?theme=light as the src instead.
https://www.discoveripo.com/ipo/nuvox-therapeutics/opengraph-image
NuvOx Therapeutics, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/nuvox-therapeutics?utm_source=embed&utm_medium=text&utm_campaign=nuvox-therapeutics
Get emailed when NuvOx Therapeutics, Inc.'s terms, price, or expected date change — no weekly noise, just this company.
NuvOx Therapeutics, Inc.'s proposed ticker is NUOX.
Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Oct 29, 2026.
View the original filing on SEC EDGAR →How this offering's SEC filings changed over time. Only SEC-sourced filings carry a full amendment history to compare; other regulators publish a single filing with no prior version to diff against.
Initial filing.
No tracked deal terms changed in this amendment.
No tracked deal terms changed in this amendment.
Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy